神经病学和神经科学杂志

  • 国际标准期刊号: 2171-6625
  • 期刊 h 指数: 17
  • 期刊引用分数: 4.43
  • 期刊影响因子: 3.38
索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 全球影响因子 (GIF)
  • 中国知网(CNKI)
  • 研究期刊索引目录 (DRJI)
  • OCLC-WorldCat
  • 普罗奎斯特传票
  • 科学期刊影响因子 (SJIF)
  • 欧洲酒吧
  • 谷歌学术
  • 秘密搜索引擎实验室
分享此页面

抽象的

Severe Guillain-Barré Syndrome Following Shingrix® Vaccine Administration

Rina Yadav*, Drew Hundley and Lannie Cation

Guillain-Barré syndrome (GBS) is a rare life threatening acute polyradiculoneuropathy with variable clinical presentations, including weakness, paresthesias, diminished deep tendon reflexes, hyponatremia, dysautonomia, and a cytoalbuminological dissociation on cerebral spinal fluid (CSF) analysis. The exact etiology remains unknown but is thought to occur as a post-infective immunemediated process. Vaccines and illnesses, including H1N1 Swine Flu vaccine, pneumococcal vaccine, Campylobacter jejuni bacteria, cytomegalovirus, and herpes zoster virus, have been associated with GBS. One vaccine that has not been identified to cause GBS is the newly released Shingrix® vaccine for herpes zoster infection prevention. We present a case of severe GBS following Shingrix® vaccine immunization.